Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Revolution Medicines, Inc.”

32 pharma patents match "Revolution Medicines, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 32
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 32 pharmaceutical patents matching "Revolution Medicines, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

32 results for “Revolution Medicines, Inc.” · 30,257 patents in full index Clear search

  1. US 12409225

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  2. US 12403196

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  3. US 12384750

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  4. US 12365688

    Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors

    Revolution Medicines, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  5. US 12280113

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  6. US 12258366

    Bicyclic heteroaryl compounds and uses thereof

    Revolution Medicines, Inc. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  7. US 12252497

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  8. US 12202845

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  9. US 12187746

    C26-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  10. US 12121522

    Methods of treating cancer with an mTOR inhibitor

    Revolution Medicines, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  11. US 12048749

    C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  12. US 11987590

    Compounds that participate in cooperative binding and uses thereof

    Revolution Medicines, Inc. · Granted May 21, 2024 · Expires May 16, 2044

    granted
  13. US 11952352

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  14. US 11739074

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Aug 29, 2023 · Expires Aug 24, 2043

    granted
  15. US 11739093

    Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors

    Revolution Medicines, Inc. · Granted Aug 29, 2023 · Expires Aug 24, 2043

    granted
  16. US 11702411

    Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors

    Revolution Medicines, Inc. · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  17. US 11690915

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  18. US 11685749

    C26-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  19. US 11673896

    Pyridine compounds as allosteric SHP2 inhibitors

    Revolution Medicines, Inc. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  20. US 11661401

    2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

    Revolution Medicines, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted
  21. US 11608346

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Mar 21, 2023 · Expires Mar 16, 2043

    granted
  22. US 11596633

    SHP2 inhibitor compositions and methods for treating cancer

    Revolution Medicines, Inc. · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  23. US 11566007

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted
  24. US 11364300

    C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted